Skip to content

Aurobindo Pharma arm enters into license agreement with US company; shares fall

Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.

Read More

​ Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide. Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish